Generation of two lymphoblastoid-derived induced pluripotent stem cell (iPSC) lines from patients with phenylketonuria

We employed a Sendai virus-based reprogramming method to transform human lymphoblastoid cell lines (LCL) derived from two individuals diagnosed with phenylketonuria (PKU) into induced pluripotent stem cells (iPSC). This reprogramming process involved the expression of the four Yamanaka factors: KLF4...

Full description

Saved in:
Bibliographic Details
Published inStem cell research Vol. 77; p. 103407
Main Authors Veleva, Desi, Ay, Merve, Ovchinnikov, Dmitry A., Prowse, Andrew B.J., Menezes, Minal J., Nafisinia, Michael
Format Journal Article
LanguageEnglish
Published England Elsevier B.V 01.06.2024
Elsevier
Subjects
Cell therapies
Drug discovery
High throughput drug screening
Human Induced pluripotent stem cells (hiPSC)
Personalised medicine
Phenylketonuria
PKU
Phenylketonuria
High throughput drug screening
Cell therapies
Personalised medicine
PKU
Human Induced pluripotent stem cells (hiPSC)
Drug discovery
Online AccessGet full text

Cover

More Information
Summary:We employed a Sendai virus-based reprogramming method to transform human lymphoblastoid cell lines (LCL) derived from two individuals diagnosed with phenylketonuria (PKU) into induced pluripotent stem cells (iPSC). This reprogramming process involved the expression of the four Yamanaka factors: KLF4, OCT4, SOX2, and C-MYC. The resulting patient-specific iPSCs exhibited a normal karyotype and expressed endogenous pluripotent markers NANOG and OCT-4. Notably, these iPSCs demonstrated strong differentiation capabilities, giving rise to cell populations representing the ectoderm, endoderm, and mesoderm germ layers.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1873-5061
1876-7753
1876-7753
DOI:10.1016/j.scr.2024.103407